Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients

CompletedOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
SchizophreniaMetabolic Syndrome
Interventions
DRUG

antipsychotic medications

olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups

DRUG

adjunctive group

antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.

DRUG

metformin and lifestyle intervention

different dose metformin combines lifestyle intervention

Trial Locations (1)

410011

Mental Health Institute of 2nd Xiangya Hospital,CSU, Changsha

All Listed Sponsors
collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Shanghai Mental Health Center

OTHER

collaborator

West China Hospital

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

Air Force Military Medical University, China

OTHER

collaborator

Jiangsu Province Nanjing Brain Hospital

OTHER

collaborator

First Affiliated Hospital of Harbin Medical University

OTHER

collaborator

Shanxi Medical University

OTHER

collaborator

First Affiliated Hospital of Kunming Medical University

OTHER

collaborator

Guangzhou Mental Hospital

OTHER

collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

collaborator

Capital Medical University

OTHER

collaborator

China Medical University, China

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

collaborator

Hebei Medical University

OTHER

collaborator

Shenzhen Mental Health Center

OTHER

collaborator

Sun Yat-sen University

OTHER

collaborator

Wuhan Mental Health Centre

OTHER

collaborator

Shanghai Jiao Tong University School of Medicine

OTHER

lead

Central South University

OTHER

NCT03451734 - Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients | Biotech Hunter | Biotech Hunter